Fully covered metal stent placement as first‐line endoscopic treatment for complicated portal cavernoma cholangiopathy

2022 ◽  
Author(s):  
Andrés Conthe ◽  
Luis Ibáñez Samaniego ◽  
Maria Vega Catalina ◽  
Oscar Nogales Rincón ◽  
Beatriz Merino ◽  
...  
Keyword(s):  
Stent Placement ◽  
Endoscopic Treatment ◽  
Metal Stent ◽  
First Line ◽  
Portal Cavernoma

scholarly journals Endoscopic full-thickness resection in a recurrent perianastomotic esophagojejunal cancer followed by fully covered metal stent placement for lumen occlusion

Endoscopy ◽  
2020 ◽  
Vol 52 (09) ◽  
pp. E337-E338
Author(s):  
Angelo Caruso ◽  
Salvatore Russo ◽  
Giuseppe Grande ◽  
Flavia Pigò ◽  
Santi Mangiafico ◽  
...  
Keyword(s):  
Stent Placement ◽  
Full Thickness ◽  
Metal Stent ◽  
Endoscopic Full Thickness Resection

Use of Prasugrel in a Patient with Clopidogrel Hypersensitivity

2011 ◽  
Vol 45 (10) ◽  
pp. 1307-1307 ◽  
Author(s):  
Sarah R Peppard ◽  
Bethanne M Held-Godgluck ◽  
Richard Beddingfield
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Stent Placement ◽  
Coronary Intervention ◽  
Bare Metal Stent ◽  
Coronary Stent ◽  
Bare Metal ◽  
Metal Stent ◽  
Therapeutic Alternative ◽  
Percutaneous Coronary ◽  
Hands And Feet

Objective: To report a case of successful use of prasugrel following percutaneous coronary intervention with placement of a bare metal stent in a patient with a documented hypersensitivity reaction to clopidogrel. Case Summary: A 61-year-old male with a history of coronary artery disease with coronary stent placement presented with ST-elevation myocardial infarction. The patient had developed Stephens-Johnson syndrome 6 years earlier following Clopidogrel administration, characterized by erythematous plaques and subsequent desquamation of the hands and feet; Clopidogrel was discontinued and he was subsequently treated with ticlopidine in addition to aspirin. The third-generation thienopyridine prasugrel was initiated as a therapeutic alternative to Clopidogrel after placement of a bare metal stent; a 60-mg dose was administered after extubation, followed by 10 mg/day. No signs of allergic reaction were observed in the days, weeks, and months following administration. Discussion: Thienopyridines, specifically Clopidogrel, are the standard of care for prevention of coronary stent thrombosis; however, there are few data available on cross-hypersensitivity between these agents. One study demonstrated that 27% of patients who developed an allergic or hematologic reaction to Clopidogrel developed a similar reaction to ticlopidine. Other therapeutic options for patients with Clopidogrel hypersensitivity who are undergoing a percutaneous coronary intervention with stent placement include Clopidogrel desensitization, warfarin plus aspirin, cilostazol, ticagrelor, and ticlopidine. However, these options are limited by efficacy and/or toxicity. With its approval in 2009, prasugrel has become a potential treatment option. Conclusions: Prasugrel may be considered a therapeutic alternative in some patients allergic or intolerant to Clopidogrel, but additional data are warranted to make a strong conclusion.

ID: 3526369 CLINICAL OUTCOMES IN PATIENTS WITH SINGLE UNCOVERED METAL STENT PLACEMENT: STENT LOCATION AND TRENDS OF ENDOSCOPIC REINTERVENTION

2021 ◽  
Vol 93 (6) ◽  
pp. AB170-AB171
Author(s):  
Shuji Mitsuhashi ◽  
Muhammad H. Bashir ◽  
Divya M. Chalikonda ◽  
Ian Holmes ◽  
Austin L. Chiang ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Stent Placement ◽  
Metal Stent
Sign in / Sign up

Export Citation Format

Share Document